CCR Milestones - 2019

Eros Lazzerini Denchi, Ph.D. Eros Lazzerini Denchi, Ph.D., has joined the Laboratory of Genome Integrity as a Stadtman Tenure Track Investigator. His research focuses on two fundamental aspects of telomere biology: the mechanism by which functional telomeres prevent DNA damage activation and the in vivo consequences of telomere dysfunction. Andres Lebensohn, Ph.D. Andres Lebensohn, Ph.D., has joined the Laboratory of Cellular and Molecular Biology as a Stadtman Tenure Track Investigator. He will develop a research program on understanding how signaling pathways are used, reused and repurposed to drive the myriad cellular processes that give rise to and maintain tissues and organs. Based on this understanding, he hopes to devise more selective therapies to target tumors driven by dysregulated WNT signaling. Ravi Madan, M.D. Ravi Madan, M.D., has been appointed as a Senior Clinician in the Genitouri- nary Malignancies Branch. His clinical research investigates immune-stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune-stimulating therapies can improve clinical outcomes and be combined with other therapies. Frank Maldarelli, M.D., Ph.D. Frank Maldarelli, M.D., Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the HIV Dynamics and Replication Program. He develops and implements clinical protocols to elucidate mechanisms underlying the emergence of HIV drug resistance in vivo, the dynamics of infection under treatment and the role of resistance mutations in the efficacy and failure of subsequent treatments. Claudia Palena, Ph.D. Claudia Palena, Ph.D., has been awarded tenure at NIH and appointed to Senior Investigator in the Laboratory of Tumor Immunology and Biology. Her laboratory studies the immunological targeting of drivers of tumor dissemination and resistance to therapy. 29